Quantitative faecal and post-mortem examinations of 16 ponies, 1 to 2 1/2 years of age, originating from 3 farms in northern Germany were performed in February 1995 to determine the prevalence and intensity of gastrointestinal parasites in these animals. A total of 33 species of metazoan parasites was recovered: three tapeworm species (Anoplocephala perfoliata, A. magna, Paranoplocephala mamillana), Strongylus vulgaris, S. edentatus, small strongyles (including four Triodontophorus spp., Craterostomum acuticaudatum and 19 cyathostome species), Oxyuris equi, Parascaris equorum, Habronema majus and Gasterophilus intestinalis larvae. Triodontophorus minor and Cylicocyclus triramosus were reported for the first time in Germany.
Download full-text PDF |
Source |
---|
BMC Cancer
January 2025
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
Background: People with malignancy of undefined primary origin (MUO) have a poor prognosis and may undergo a protracted diagnostic workup causing patient distress and high cancer related costs. Not having a primary diagnosis limits timely site-specific treatment and access to precision medicine. There is a need to improve the diagnostic process, and healthcare delivery and support for these patients.
View Article and Find Full Text PDFNature
January 2025
International Union for the Conservation of Nature (IUCN) Conservation Genetics Specialist Group (CGSG), .
Mitigating loss of genetic diversity is a major global biodiversity challenge. To meet recent international commitments to maintain genetic diversity within species, we need to understand relationships between threats, conservation management and genetic diversity change. Here we conduct a global analysis of genetic diversity change via meta-analysis of all available temporal measures of genetic diversity from more than three decades of research.
View Article and Find Full Text PDFNat Commun
January 2025
Centre for Marine Magnetism (CM2, Department of Ocean Science and Engineering, Southern University of Science and Technology, Shenzhen, 518055, China.
Under sustained global warming, Arctic climate is projected to become more responsive to changes in North Pacific meridional heat transport as a result of teleconnections between low and high latitudes, but the underlying mechanisms remain poorly understood. Here, we reconstruct subarctic humidity changes over the past 400 kyr to investigate the role of low-to-high latitude interactions in regulating Arctic hydroclimate. Our reconstruction is based on precipitation-driven sediment input variations in the Subarctic North Pacific (SANP), which reveal a strong precessional cycle in subarctic humidity under the relatively low eccentricity variations that dominated the past four glacial-interglacial cycles.
View Article and Find Full Text PDFPhys Rev Lett
December 2024
CERN, Geneva, Switzerland.
Z boson events at the Large Hadron Collider can be selected with high purity and are sensitive to a diverse range of QCD phenomena. As a result, these events are often used to probe the nature of the strong force, improve Monte Carlo event generators, and search for deviations from standard model predictions. All previous measurements of Z boson production characterize the event properties using a small number of observables and present the results as differential cross sections in predetermined bins.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!